June 10, 2024 Regulatory Kommuniké från extra bolagsstämmor i InDex Pharmaceuticals Holding AB (publ) den 10 juni 2024 Read more
June 10, 2024 Regulatory Bulletin from the Extraordinary General Meetings in InDex Pharmaceuticals Holding AB (publ) on June 10, 2024 Read more
June 7, 2024 Regulatory InDex Pharmaceuticals har erhållit villkorat godkännande för fortsatt notering på Nasdaq First North Growth Market efter det omvända förvärvet av Flerie Read more
June 7, 2024 Regulatory InDex Pharmaceuticals has received a conditional approval for continued listing on Nasdaq First North Growth Market after the reverse merger of Flerie Read more
June 5, 2024 Regulatory Rättelse: InDex Pharmaceuticals offentliggör Fleries substansvärde per 31 maj 2024 Read more
June 4, 2024 Regulatory InDex Pharmaceuticals offentliggör Fleries substansvärde per 31 maj 2024 Read more
May 27, 2024 Regulatory InDex Pharmaceuticals publishes company description in connection with the reverse merger of Flerie Read more
May 27, 2024 Regulatory InDex Pharmaceuticals offentliggör bolagsbeskrivning med anledning av det omvända förvärvet av Flerie Read more
May 23, 2024 Regulatory Notice of extraordinary general meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 23, 2024 Regulatory InDex Pharmaceuticals Holding AB (publ) kallar till extra bolagsstämma Read more
May 20, 2024 Regulatory InDex Pharmaceuticals has entered into a conditional agreement regarding a reverse merger with Flerie Read more
May 20, 2024 Regulatory InDex Pharmaceuticals har ingått villkorat avtal om omvänt förvärv av Flerie Read more
May 7, 2024 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 6, 2024 Regulatory InDex Pharmaceuticals Holding AB (publ) kallar till extra bolagsstämma Read more
May 6, 2024 Regulatory Notice of extraordinary general meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 6, 2024 Non Regulatory InDex Pharmaceuticals provides a status update and informs about Extraordinary General Meeting on June 10, 2024 Read more
May 6, 2024 Non Regulatory InDex Pharmaceuticals lämnar en statusuppdatering och informerar om extra bolagsstämma den 10 juni 2024 Read more
April 26, 2024 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2024 Read more
April 26, 2024 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – mars 2024 Read more
April 22, 2024 Regulatory InDex Pharmaceuticals tidigarelägger publicering av delårsrapport för första kvartalet 2024 Read more
April 22, 2024 Regulatory InDex Pharmaceuticals brings forward the publication of the interim report for Q1 2024 Read more
April 8, 2024 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2023 Read more
April 8, 2024 Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör årsredovisning för 2023 Read more
April 5, 2024 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
February 26, 2024 Non Regulatory InDex Pharmaceuticals provides an update on company’s future Read more
February 26, 2024 Non Regulatory InDex Pharmaceuticals ger en uppdatering om bolagets framtid Read more
February 26, 2024 Non Regulatory InDex Pharmaceuticals ger en uppdatering om bolagets framtid Read more
February 26, 2024 Regulatory InDex Pharmaceuticals discontinues the development of cobitolimod Read more
February 21, 2024 Regulatory InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2023 Read more
January 19, 2024 Regulatory InDex Pharmaceuticals announces expected cash balance per March 31, 2024 Read more
January 19, 2024 Regulatory InDex Pharmaceuticals meddelar förväntade likvida medel per 31 mars 2024 Read more
November 28, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January-September 2023 Read more
November 28, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari-september 2023 Read more
November 21, 2023 Regulatory InDex Pharmaceuticals discontinues cobitolimod phase III program Read more
November 21, 2023 Regulatory InDex Pharmaceuticals avbryter fas III-programmet med cobitolimod Read more
November 21, 2023 Regulatory InDex Pharmaceuticals avbryter fas III-programmet med cobitolimod Read more
October 30, 2023 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2024 Annual General Meeting Read more
October 30, 2023 Non Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör valberedning inför årsstämman 2024 Read more
October 20, 2023 Non Regulatory InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea Read more
October 20, 2023 Non Regulatory InDex Pharmaceuticals har beviljats ett nytt patent för cobitolimod i Sydkorea Read more
October 11, 2023 Non Regulatory InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE Read more
October 11, 2023 Non Regulatory InDex Pharmaceuticals meddelar att alla patienter som krävs för att nå milstolpen för dosvalet av cobitolimod har slutfört Induktionsstudie 1 av fas III-programmet CONCLUDE Read more
October 5, 2023 Non Regulatory InDex Pharmaceuticals deltar vid United European Gastroenterology Week 2023 Read more
August 23, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2023 Read more
August 23, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – juni 2023 Read more
August 22, 2023 Non Regulatory ”Positive results from PK study with cobitolimod” selected as one of the best abstracts for poster presentation at UEGW Read more
August 22, 2023 Non Regulatory ”Positiva resultat från PK-studie med cobitolimod” utsedd till en av de bästa abstrakten för posterpresentation vid UEGW Read more
August 2, 2023 Regulatory InDex Pharmaceuticals has been granted a new patent in Europe for the commercial formulation of cobitolimod Read more
August 2, 2023 Regulatory InDex Pharmaceuticals har beviljats ett nytt patent i Europa för den kommersiella formuleringen av cobitolimod Read more
May 31, 2023 Non Regulatory InDex Pharmaceuticals investeraruppdatering 1 juni kl. 15:00 CET Read more
May 31, 2023 Non Regulatory InDex Pharmaceuticals investeraruppdatering 1 juni kl. 15:00 CET Read more
May 31, 2023 Regulatory InDex Pharmaceuticals announces license agreement with Viatris Japan to develop and commercialize cobitolimod in Japan Read more
May 31, 2023 Regulatory InDex Pharmaceuticals och Viatris Japan ingår licensavtal för att utveckla och kommersialisera cobitolimod i Japan Read more
May 24, 2023 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 24, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2023 Read more
May 24, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – mars 2023 Read more
April 26, 2023 Non Regulatory Welcome to an InDex Pharmaceuticals business update presentation in Stockholm on May 9, from 13:00 to 15.30 CET Read more
April 26, 2023 Non Regulatory Välkommen till InDex Pharmaceuticals Business Update-presentation i Stockholm den 9 maj, kl 13:00 till 15.30 CET Read more
April 19, 2023 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 12, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2022 Read more
April 12, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör årsredovisning för 2022 Read more
March 15, 2023 Non Regulatory InDex Pharmaceuticals announces positive results from a pharmacokinetic (PK) study with cobitolimod Read more
March 15, 2023 Non Regulatory InDex Pharmaceuticals meddelar positiva resultat från en farmakokinetikstudie (PK-studie) med cobitolimod Read more
February 23, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2022 Read more
February 14, 2023 Non Regulatory InDex Pharmaceuticals provides complementary information on the phase III program CONCLUDE with cobitolimod Read more
February 14, 2023 Non Regulatory InDex Pharmaceuticals tillhandahåller kompletterande information om fas III-programmet CONCLUDE med cobitolimod Read more
January 27, 2023 Regulatory InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod Read more
January 27, 2023 Regulatory InDex Pharmaceuticals uppdaterar tidplanen för fas III-studien CONCLUDE med cobitolimod Read more
November 23, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2022 Read more
November 23, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – september 2022 Read more
October 26, 2022 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2023 Annual General Meeting Read more
October 26, 2022 Non Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör valberedning inför årsstämman 2023 Read more
October 5, 2022 Non Regulatory InDex Pharmaceuticals to exhibit at United European Gastroenterology Week Read more
October 5, 2022 Non Regulatory InDex Pharmaceuticals deltar som utställare på United European Gastroenterology Week Read more
August 26, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2022 Read more
August 26, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – juni 2022 Read more
August 16, 2022 Non Regulatory InDex Pharmaceuticals announces successful interactions with the PMDA for the clinical development of cobitolimod in Japan Read more
August 16, 2022 Non Regulatory InDex Pharmaceuticals meddelar framgångsrika interaktioner med PMDA för den kliniska utvecklingen av cobitolimod i Japan Read more
July 13, 2022 Regulatory InDex Pharmaceuticals gets new patent for cobitolimod granted in Europe Read more
July 13, 2022 Regulatory InDex Pharmaceuticals får nytt patent för cobitolimod beviljat i Europa Read more
June 1, 2022 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 16, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2022 Read more
May 16, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – mars 2022 Read more
May 12, 2022 Non Regulatory InDex Pharmaceuticals deltar som utställare på Digestive Disease Week Read more
May 2, 2022 Regulatory InDex Pharmaceuticals strengthens the organization with Eva Arlander as Chief Development Officer and announces changes in the composition of the management team Read more
May 2, 2022 Regulatory InDex Pharmaceuticals stärker organisationen med Eva Arlander som Chief Development Officer samt presenterar förändringar i ledningsgruppens sammansättning Read more
April 28, 2022 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 8, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör årsredovisning för 2021 Read more
April 8, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2021 Read more
March 13, 2022 Regulatory InDex Pharmaceuticals prepares for commercialisation of cobitolimod Read more
March 13, 2022 Regulatory InDex Pharmaceuticals prepares for commercialisation of cobitolimod Read more
March 13, 2022 Regulatory InDex Pharmaceuticals förbereder kommersialisering av cobitolimod Read more
March 7, 2022 Non Regulatory Reminder: InDex Pharmaceuticals hosts Capital Markets Day on March 14, 2022 Read more
March 7, 2022 Non Regulatory Påminnelse: InDex Pharmaceuticals arrangerar kapitalmarknadsdag den 14 mars 2022 Read more
February 23, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2021 Read more
February 15, 2022 Non Regulatory Invitation to InDex Pharmaceuticals’ Capital Markets Day on March 14, 2022 Read more
February 15, 2022 Non Regulatory Inbjudan till InDex Pharmaceuticals kapitalmarknadsdag den 14 mars 2022 Read more
February 13, 2022 Regulatory COO Pernilla Sandwall is leaving InDex Pharmaceuticals for a CEO position Read more
February 13, 2022 Regulatory COO Pernilla Sandwall lämnar InDex Pharmaceuticals för en VD-roll Read more
December 8, 2021 Non Regulatory InDex Pharmaceuticals enrols first patient in the PK study with cobitolimod Read more
December 8, 2021 Non Regulatory InDex Pharmaceuticals inkluderar första patienten i PK-studien med cobitolimod Read more
November 24, 2021 Regulatory InDex Pharmaceuticals enrols first patient in the phase III study CONCLUDE with cobitolimod in ulcerative colitis Read more
November 24, 2021 Regulatory InDex Pharmaceuticals inkluderar första patienten i fas III-studien CONCLUDE med cobitolimod i ulcerös kolit Read more
November 24, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – september 2021 Read more
November 24, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2021 Read more
November 16, 2021 Regulatory InDex Pharmaceuticals gets new patent for cobitolimod granted in Canada Read more
November 16, 2021 Regulatory InDex Pharmaceuticals får nytt patent för cobitolimod beviljat i Kanada Read more
November 10, 2021 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2022 Annual General Meeting Read more
November 10, 2021 Non Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör valberedning inför årsstämman 2022 Read more
November 9, 2021 Regulatory InDex Pharmaceuticals gets new patent for cobitolimod granted in the US Read more
November 9, 2021 Regulatory InDex Pharmaceuticals får nytt patent för cobitolimod beviljat i USA Read more
November 8, 2021 Non Regulatory InDex Pharmaceuticals presents at Redeye Life Science Day 2021 Read more
November 8, 2021 Non Regulatory InDex Pharmaceuticals presenterar på Redeye Life Science Day 2021 Read more
August 25, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2021 Read more
August 25, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – juni 2021 Read more
August 24, 2021 Regulatory InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod Read more
August 24, 2021 Regulatory InDex Pharmaceuticals får FDA-godkännande att starta fas III-studien CONCLUDE med cobitolimod Read more
August 23, 2021 Non Regulatory InDex Pharmaceuticals strengthens the clinical development organization in preparation of the start of the phase III study CONCLUDE with cobitolimod Read more
August 23, 2021 Non Regulatory InDex Pharmaceuticals stärker sin kliniska utvecklingsorganisation inför starten av fas III-studien CONCLUDE med cobitolimod Read more
July 21, 2021 Regulatory InDex Pharmaceuticals receives first regulatory approval to start the phase III study CONCLUDE with cobitolimod Read more
July 21, 2021 Regulatory InDex Pharmaceuticals får första regulatoriska godkännandet att starta fas III-studien CONCLUDE med cobitolimod Read more
June 3, 2021 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 31, 2021 Regulatory InDex Pharmaceuticals inleder patientrekryteringen till fas III-studien CONCLUDE efter sommaren Read more
May 31, 2021 Regulatory InDex Pharmaceuticals will initiate patient recruitment for the Phase III study CONCLUDE after the summer Read more
May 5, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2021 Read more
May 5, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – mars 2021 Read more
May 4, 2021 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 23, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör årsredovisning för 2020 Read more
April 23, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2020 Read more
April 7, 2021 Non Regulatory InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe Read more
April 7, 2021 Non Regulatory InDex Pharmaceuticals får patent på ytterligare DIMS-substanser beviljat i Europa Read more
March 30, 2021 Non Regulatory InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis Read more
March 30, 2021 Non Regulatory InDex Pharmaceuticals ingår avtal med Parexel Biotech för klinisk fas III-studie med cobitolimod Read more
March 15, 2021 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces changes in the Nomination Committee for the 2021 Annual General Meeting Read more
March 15, 2021 Non Regulatory InDex Pharmaceuticals Holding AB (publ) meddelar förändringar i valberedningens sammansättning inför årsstämman 2021 Read more
March 10, 2021 Non Regulatory InDex Pharmaceuticals presents at Barclays Global Healthcare Conference and Carnegie Nordic Virtual Healthcare Seminar Read more
March 10, 2021 Non Regulatory InDex Pharmaceuticals presenterar på Barclays Global Healthcare Conference och Carnegie Nordic Virtual Healthcare Seminar Read more
February 25, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2020 Read more
January 21, 2021 Regulatory InDex Pharmaceuticals Holding AB publishes prospectus in connection with a fully guaranteed rights issue Read more
January 21, 2021 Regulatory InDex Pharmaceuticals Holding AB offentliggör prospekt i samband med fullt garanterad företrädesemission Read more
January 14, 2021 Regulatory The board of directors of InDex Pharmaceuticals Holding AB has resolved on a fully guaranteed rights issue of approximately MSEK 533 Read more
January 14, 2021 Regulatory Styrelsen för InDex Pharmaceuticals Holding AB har beslutat om en fullt garanterad företrädesemission om cirka 533 miljoner kronor Read more
January 12, 2021 Regulatory Bulletin from the Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
January 12, 2021 Regulatory Kommuniké från extra bolagsstämma i InDex Pharmaceuticals Holding AB (publ) Read more
December 9, 2020 Regulatory Notice of Extraordinary General Meeting in InDex Pharmaceuticals Holding AB Read more
December 9, 2020 Regulatory InDex Pharmaceuticals Holding AB kallar till extra bolagsstämma Read more
December 3, 2020 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2021 Annual General Meeting Read more
December 3, 2020 Non Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör valberedning inför årsstämman 2021 Read more
November 26, 2020 Non Regulatory InDex Pharmaceuticals to host virtual R&D day on December 8, 2020 Read more
November 26, 2020 Non Regulatory InDex Pharmaceuticals arrangerar virtuell FoU-dag den 8 december 2020 Read more
November 25, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2020 Read more
November 25, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – september 2020 Read more
November 25, 2020 Regulatory InDex Pharmaceuticals intends to carry out a fully guaranteed rights issue of approximately SEK 500 million to fund phase III development of cobitolimod Read more
November 25, 2020 Regulatory InDex Pharmaceuticals avser att genomföra en fullt garanterad företrädesemission om cirka 500 miljoner kronor för att finansiera fas III-utveckling av cobitolimod Read more
November 24, 2020 Non Regulatory InDex Pharmaceuticals presents at Redeye Life Science Day 2020 Read more
November 24, 2020 Non Regulatory InDex Pharmaceuticals presenterar på Redeye Life Science Day 2020 Read more
October 6, 2020 Non Regulatory Lancet Gastroenterology and Hepatology publicerar resultaten från InDex Pharmaceuticals fas IIb-studie med cobitolimod Read more
October 6, 2020 Non Regulatory The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals’ results of the phase IIb study with cobitolimod Read more
August 26, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – juni 2020 Read more
August 26, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2020 Read more
August 24, 2020 Non Regulatory InDex Pharmaceuticals to present the successful results of the CONDUCT study at two leading medical conferences Read more
August 24, 2020 Non Regulatory InDex Pharmaceuticals presenterar de positiva resultaten från CONDUCT-studien vid två ledande medicinska konferenser Read more
May 7, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2020 Read more
May 7, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – mars 2020 Read more
April 20, 2020 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 20, 2020 Regulatory Kommuniké från årsstämma i InDex Pharmaceuticals Holding AB (publ) Read more
April 16, 2020 Regulatory InDex Pharmaceuticals advances cobitolimod further towards phase III following successful interactions with FDA and EMA Read more
April 16, 2020 Regulatory FDA och EMA ger klartecken för InDex Pharmaceuticals att ta cobitolimod vidare till fas III Read more
April 8, 2020 Non Regulatory Update on InDex Pharmaceuticals Holding AB’s (InDex) Annual General Meeting addressing covid-19 Read more
April 8, 2020 Non Regulatory Information om InDex Pharmaceuticals Holding AB’s (InDex) årsstämma 2020 med anledning av covid-19 Read more
March 31, 2020 Non Regulatory InDex Pharmaceuticals receives grant from Vinnova for pre-clinical development of DIMS compounds in inflammation Read more
March 31, 2020 Non Regulatory InDex Pharmaceuticals får finansiering från Vinnova för preklinisk utveckling av DIMS-substanser mot inflammatoriska sjukdomar Read more
March 30, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2019 Read more
March 30, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör årsredovisning för 2019 Read more
March 19, 2020 Regulatory Notice to attend the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
February 25, 2020 Non Regulatory InDex Pharmaceuticals publishes mechanism of action data for cobitolimod in scientific journal Read more
February 25, 2020 Non Regulatory InDex Pharmaceuticals publicerar data om cobitolimods verkningsmekanism i vetenskaplig tidskrift Read more
February 20, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2019 Read more
February 19, 2020 Regulatory InDex Pharmaceuticals’ in-depth analysis of the CONDUCT study confirms the successful top line results and supports the strategy going forward Read more
February 19, 2020 Regulatory InDex Pharmaceuticals fördjupade analys av CONDUCT-studien bekräftar de starka huvudresultaten och stödjer strategin framåt Read more
December 6, 2019 Non Regulatory InDex bjuder in till verksamhetsuppdatering den 12 december Read more
November 27, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2019 Read more
November 27, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – september 2019 Read more
November 18, 2019 Non Regulatory InDex Pharmaceuticals presents at Redeye Life Science Day and Avanza Börsdag November 19, 2019 Read more
November 18, 2019 Non Regulatory InDex Pharmaceuticals presenterar på Redeye Life Science Day och Avanza Börsdag 19 november 2019 Read more
November 1, 2019 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2020 Annual General Meeting Read more
November 1, 2019 Non Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör valberedning inför årsstämman 2020 Read more
October 24, 2019 Non Regulatory InDex Pharmaceuticals presents today at Redeye Investor After Work Read more
October 24, 2019 Non Regulatory InDex Pharmaceuticals presenterar idag på Redeye Investor After Work Read more
October 9, 2019 Regulatory Bulletin from Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
October 9, 2019 Regulatory Kommuniké från extra bolagsstämma i InDex Pharmaceuticals Holding AB (publ) Read more
September 19, 2019 Regulatory Notice of Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
September 19, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) kallar till extra bolagsstämma Read more
September 19, 2019 Regulatory InDex Pharmaceuticals has completed a directed share issue of approximately SEK 140 million (USD 14 million) Read more
September 19, 2019 Regulatory InDex Pharmaceuticals har genomfört en riktad nyemission av aktier om cirka SEK 140 miljoner (USD 14 miljoner) Read more
September 19, 2019 Regulatory InDex Pharmaceuticals offentliggör avsikt att genomföra riktad nyemission av aktier Read more
September 19, 2019 Regulatory InDex Pharmaceuticals announces intention of a directed share issue Read more
August 27, 2019 Regulatory InDex Pharmaceuticals meets primary endpoint in the phase IIb study CONDUCT with cobitolimod in ulcerative colitis Read more
August 27, 2019 Regulatory InDex Pharmaceuticals möter primära effektmåttet i fas IIb-studien CONDUCT med cobitolimod i ulcerös kolit Read more
August 15, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2019 Read more
August 15, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – juni 2019 Read more
June 26, 2019 Regulatory InDex Pharmaceuticals enrolls last patient in phase IIb study CONDUCT with cobitolimod Read more
June 26, 2019 Regulatory InDex Pharmaceuticals inkluderar sista patienten i fas IIb-studien CONDUCT med cobitolimod Read more
June 3, 2019 Non Regulatory InDex Pharmaceuticals presents at Redeye Growth Day on June 10, 2019 Read more
June 3, 2019 Non Regulatory InDex Pharmaceuticals presenterar på Redeye Growth Day, 10 juni 2019 Read more
May 6, 2019 Regulatory Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 6, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2019 Read more
May 6, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – mars 2019 Read more
April 11, 2019 Regulatory InDex Pharmaceuticals provides status update on the patient recruitment in the CONDUCT study Read more
April 11, 2019 Regulatory InDex Pharmaceuticals ger statusuppdatering avseende patientrekryteringen i CONDUCT-studien Read more
April 5, 2019 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 2, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2018 Read more
April 2, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör årsredovisning för 2018 Read more
February 20, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2018 Read more
November 19, 2018 Non Regulatory InDex Pharmaceuticals presenterar på Redeye Life Science Day 21 november 2018 Read more
November 19, 2018 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2018 Read more
November 19, 2018 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – september 2018 Read more
November 6, 2018 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2019 Annual General Meeting Read more
November 6, 2018 Non Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör valberedning inför årsstämman 2019 Read more
October 23, 2018 Regulatory InDex Pharmaceuticals carries out a directed share issue of approximately SEK 37.5 million Read more
October 23, 2018 Regulatory InDex Pharmaceuticals genomför riktad nyemission om cirka 37,5 MSEK Read more
October 19, 2018 Non Regulatory InDex Pharmaceuticals publicerar post-hoc analys av COLLECT-studien Read more
October 19, 2018 Non Regulatory InDex Pharmaceuticals publishes post-hoc analysis of the COLLECT study Read more
August 28, 2018 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2018 Read more
August 28, 2018 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – juni 2018 Read more
August 9, 2018 Regulatory InDex Pharmaceuticals updates timeline for top line results from the CONDUCT study to first half of 2019 Read more
August 9, 2018 Regulatory InDex Pharmaceuticals uppdaterar tidsplanen för huvudresultaten från CONDUCT-studien till första halvåret 2019 Read more
May 31, 2018 Non Regulatory InDex Pharmaceuticals will participate in the Digestive Disease Week (DDW) Read more
May 24, 2018 Regulatory Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 17, 2018 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2018 Read more
May 17, 2018 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – mars 2018 Read more
April 24, 2018 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2017 Read more
April 24, 2018 Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör årsredovisning för 2017 Read more
April 23, 2018 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 12, 2018 Non Regulatory InDex Pharmaceuticals announces the agenda for its Capital Markets Day in Stockholm on April 25, 2018 Read more
April 12, 2018 Non Regulatory InDex Pharmaceuticals tillkännager agenda inför kapitalmarknadsdag i Stockholm den 25 april 2018 Read more
March 26, 2018 Non Regulatory Save the date: InDex Pharmaceuticals to host Capital Markets Day in Stockholm on April 25, 2018 Read more
March 26, 2018 Non Regulatory Save the date: InDex Pharmaceuticals arrangerar kapitalmarknadsdag i Stockholm den 25 april 2018 Read more
March 5, 2018 Non Regulatory InDex Pharmaceuticals presenterar på Stockholm Corporate Finance Life Science Seminarium Read more
February 26, 2018 Regulatory InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2017 Read more
February 13, 2018 Non Regulatory InDex Pharmaceuticals presents mechanism of action data for cobitolimod at the ECCO congress Read more
February 13, 2018 Non Regulatory InDex Pharmaceuticals presenterar data om cobitolimods verkningsmekanism på ECCO-kongressen Read more
December 1, 2017 Regulatory InDex Pharmaceuticals rapporterar nya data om cobitolimods verkningsmekanism Read more
December 1, 2017 Regulatory InDex Pharmaceuticals reports new mechanism of action data for cobitolimod Read more
November 21, 2017 Non Regulatory InDex Pharmaceuticals presenterar på Redeye Life Science Seminar 24 november 2017 Read more
November 17, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – september 2017 Read more
November 17, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2017 Read more
November 16, 2017 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee and financial reporting dates for 2018 Read more
November 16, 2017 Non Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör valberedning och datum för finansiell rapportering 2018 Read more
October 26, 2017 Non Regulatory InDex Pharmaceuticals will participate in the United European Gastroenterology Week (UEGW) Read more
October 26, 2017 Non Regulatory InDex Pharmaceuticals deltar på United European Gastroenterology Week (UEGW) Read more
August 25, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – juni 2017 Read more
August 25, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2017 Read more
August 9, 2017 Non Regulatory InDex Pharmaceuticals receives orphan-drug designation for pediatric ulcerative colitis in the US Read more
August 9, 2017 Non Regulatory InDex Pharmaceuticals får särläkemedelsstatus för pediatrisk ulcerös kolit beviljad i USA Read more
June 21, 2017 Regulatory InDex Pharmaceuticals enrolls first patient in the phase IIb study CONDUCT with cobitolimod Read more
June 21, 2017 Regulatory InDex Pharmaceuticals inkluderar första patienten i fas IIb-studien CONDUCT med cobitolimod Read more
May 30, 2017 Regulatory Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 30, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2017 Read more
May 30, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – mars 2017 Read more
May 5, 2017 Non Regulatory InDex Pharmaceuticals will participate in the Digestive Disease Week (DDW) Read more
April 27, 2017 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 27, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2016 Read more
April 27, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör årsredovisning för 2016 Read more
March 22, 2017 Non Regulatory InDex Pharmaceuticals concludes well attended Investigators’ Meeting for the phase IIb study CONDUCT Read more
March 22, 2017 Non Regulatory InDex Pharmaceuticals har genomfört ett välbesökt prövarmöte för fas IIb-studien CONDUCT Read more
March 20, 2017 Non Regulatory InDex Pharmaceuticals presenterar på Stockholm Corporate Finance Life Science Seminarium Read more
March 14, 2017 Regulatory InDex Pharmaceuticals gets patent for additional DIMS compounds granted in the US Read more
March 14, 2017 Regulatory InDex Pharmaceuticals får patent på ytterligare DIMS-substanser beviljat i USA Read more
February 27, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2016 Read more
February 1, 2017 Regulatory InDex Pharmaceuticals enters agreement with CRO for the CONDUCT study Read more
January 23, 2017 Non Regulatory InDex Pharmaceuticals will participate in the European Crohn’s and Colitis Organisation (ECCO) Congress Read more
January 23, 2017 Non Regulatory InDex Pharmaceuticals deltar på europeiska Crohns- och kolit-organisationens (ECCO) kongress Read more
November 22, 2016 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – september 2016 Read more
November 22, 2016 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2016 Read more
October 18, 2016 Non Regulatory Results from InDex Pharmaceuticals’ COLLECT study well received at UEGW Read more
October 18, 2016 Non Regulatory Resultat från InDex Pharmaceuticals COLLECT-studie väl mottagna vid UEGW Read more
October 10, 2016 Non Regulatory InDex Pharmaceuticals presents results from the COLLECT study at the United European Gastroenterology Week 2016 Read more
October 10, 2016 Non Regulatory InDex Pharmaceuticals presenterar resultat från COLLECT-studien vid United European Gastroenterology Week 2016 Read more
September 30, 2016 Non Regulatory InDex Pharmaceuticals announces the outcome of its initial public offering in connection with planned listing on Nasdaq First North Stockholm Read more
September 30, 2016 Non Regulatory InDex Pharmaceuticals offentliggör utfall i nyemission av aktier i samband med planerad listning på Nasdaq First North Stockholm Read more
September 26, 2016 Non Regulatory InDex Pharmaceuticals ends the subscription period for the initial public offering in connection with listing on Nasdaq First North Tuesday, September 27 Read more
September 26, 2016 Non Regulatory InDex Pharmaceuticals avslutar teckningsperiod för nyemission inför notering på Nasdaq First North tisdag 27 september Read more
September 14, 2016 Non Regulatory InDex Pharmaceuticals initiates the subscription period for the initial public offering in connection with planned listing on Nasdaq First North Read more
September 14, 2016 Non Regulatory InDex Pharmaceuticals inleder teckningsperiod för nyemission inför notering på Nasdaq First North Read more
September 13, 2016 Non Regulatory InDex Pharmaceuticals offentliggör prospekt avseende nyemission i samband med planerad listning på Nasdaq First North Stockholm Read more
September 13, 2016 Non Regulatory InDex Pharmaceuticals publishes prospectus regarding initial public offering in connection with planned listing on Nasdaq First North Stockholm Read more
September 13, 2016 Non Regulatory InDex Pharmaceuticals genomför nyemission i samband med planerad listning på Nasdaq First North Stockholm Read more
September 13, 2016 Non Regulatory InDex Pharmaceuticals conducts initial public offering in connection with planned listing on Nasdaq First North Stockholm Read more
August 25, 2016 Non Regulatory InDex Pharmaceuticals Holding AB – Delårsrapport 27 juni – 30 juni 2016 Read more
August 25, 2016 Non Regulatory InDex Pharmaceuticals Holding AB – Interim Report 27 June – 30 June 2016 Read more
August 15, 2016 Non Regulatory InDex Pharmaceuticals AB – Delårsrapport januari – juni 2016 Read more
August 15, 2016 Non Regulatory InDex Pharmaceuticals AB – Interim Report January – June 2016 Read more
July 13, 2016 Non Regulatory InDex Pharmaceuticals publicerar resultat från COLLECT-studien Read more
May 23, 2016 Non Regulatory InDex Pharmaceuticals receives grant from Sweden´s innovation agency Vinnova for pre-clinical development of DIMS compounds in inflammation Read more
May 23, 2016 Non Regulatory InDex Pharmaceuticals får finansiering från Vinnova för preklinisk utveckling av DIMS-substanser mot inflammatoriska sjukdomar Read more
March 7, 2016 Non Regulatory InDex Pharmaceuticals Receives FDA Clearance of IND for Cobitolimod (Kappaproct®) Phase IIb Trial Read more
March 7, 2016 Non Regulatory InDex Pharmaceuticals erhåller FDA-godkännande av IND för fas IIb-studie med cobitolimod (Kappaproct®) Read more
February 10, 2016 Non Regulatory InDex Pharmaceuticals receives approval of the International Nonproprietary Name (INN) cobitolimod for their lead drug candidate Kappaproct® Read more
February 10, 2016 Non Regulatory InDex Pharmaceuticals erhåller godkännande av det internationella generiska namnet (INN) cobitolimod för sin ledande läkemedelskandidat Kappaproct® Read more
August 20, 2015 Non Regulatory InDex Pharmaceuticals AB – Interim Report January – June 2015 Read more
August 20, 2015 Non Regulatory InDex Pharmaceuticals AB – Delårsrapport januari – juni 2015 Read more
July 9, 2015 Non Regulatory InDex Pharmaceuticals appoints Uli Hacksell and Jesper Wiklund to its Board of Directors Read more
July 9, 2015 Non Regulatory InDex Pharmaceuticals utser Uli Hacksell och Jesper Wiklund till nya styrelseledamöter Read more
June 30, 2015 Non Regulatory InDex Pharmaceuticals regains European rights to Kappaproct® in ulcerative colitis Read more
June 30, 2015 Non Regulatory InDex Pharmaceuticals återfår europeiska rättigheterna till Kappaproct® för ulcerös kolit Read more
February 3, 2015 Non Regulatory InDex Pharmaceuticals to present results from the COLLECT trial at the 10th Congress of the European Crohn’s and Colitis Organisation Read more
February 3, 2015 Non Regulatory InDex Pharmaceuticals presenterar resultat från COLLECT-studien vid europeiska Crohns- och kolit-organisationens 10:e kongress Read more
June 27, 2014 Non Regulatory InDex Pharmaceuticals announces results from COLLECT, a clinical trial of Kappaproct® in the treatment of moderate to severe Ulcerative Colitis Read more
June 27, 2014 Non Regulatory InDex Pharmaceuticals presenterar resultat från COLLECT, en klinisk studie av Kappaproct® för behandling av måttlig till svår ulcerös kolit Read more
April 1, 2014 Non Regulatory InDex Pharmaceuticals och Almirall ingår licensavtal för de europeiska rättigheterna till fas III läkemedelskandidaten Kappaproct Read more
April 1, 2014 Non Regulatory InDex Pharmaceuticals and Almirall enter into a license agreement for European rights of the phase III drug candidate Kappaproct Read more
February 25, 2014 Non Regulatory InDex Pharmaceuticals slutför finansieringsrunda om USD 20 m (EUR 15 m) och välkomnar NeoMed som ny aktieägare Read more
February 25, 2014 Non Regulatory InDex Pharmaceuticals closes $20 m financing round and welcomes NeoMed as new shareholder Read more
April 8, 2013 Non Regulatory InDex Pharmaceuticals reports completion of patient recruitment in Phase III Ulcerative Colitis Study (COLLECT) with Kappaproct Read more
April 8, 2013 Non Regulatory InDex Pharmaceuticals meddelar slutförandet av patientrekrytering i fas III ulcerös kolit studie (COLLECT) med Kappaproct Read more
October 24, 2012 Non Regulatory InDex Pharmaceuticals Granted Japanese Patent for Novel Treatment of Steroid-Resistant Inflammation Read more
October 24, 2012 Non Regulatory InDex Pharmaceuticals beviljas japanskt patent för ny behandling av steroidresistent inflammation Read more
August 30, 2012 Non Regulatory InDex Pharmaceuticals Strengthens IP Position for Kappaproct Read more
August 30, 2012 Non Regulatory InDex Pharmaceuticals utökar patentportföljen för läkemedelskandidaten Kappaproct Read more
July 9, 2012 Non Regulatory InDex publish positive results from Kappaproct Compassionate Use program Read more
June 19, 2012 Non Regulatory Kappaproct minskar behovet av kirurgiskt ingrepp för patienter med svår ulcerös kolit Read more
June 19, 2012 Non Regulatory Kappaproct Drastically Reduces the Need for Colectomy in Patients with Severe Ulcerative Colitis Read more
May 29, 2012 Non Regulatory InDex Pharmaceuticals utser Stig Løkke Pedersen till styrelseledamot Read more
May 29, 2012 Non Regulatory InDex Pharmaceuticals Appoints Stig Løkke Pedersen as Board Member Read more
April 26, 2012 Non Regulatory InDex Pharmaceuticals Granted US Patent for Novel Treatment of Steroid-Resistant Inflammation Read more
April 26, 2012 Non Regulatory InDex Pharmaceuticals beviljas amerikanskt patent för ny behandling av steroidresistent inflammation Read more
March 20, 2012 Non Regulatory InDex Pharmaceuticals utvecklar companion diagnostics för ny ulcerös kolit behandling Read more
March 20, 2012 Non Regulatory InDex Pharmaceuticals develops companion diagnostic test for new ulcerative colitis therapy. Read more
March 6, 2012 Non Regulatory InDex Pharmaceuticals Starts Phase III COLLECT Study with Kappaproct Read more
March 6, 2012 Non Regulatory InDex Pharmaceuticals startar fas III studien COLLECT för Kappaproct Read more
October 24, 2011 Non Regulatory InDex Pharmaceuticals participates at the UEGW (19th United European Gastroenterology Week) at Stockholmsmässan Oct 24-26. Read more
July 7, 2011 Non Regulatory InDex Pharmaceuticals names Jesper Wiklund Chief Executive Officer Read more
May 17, 2011 Non Regulatory InDex Pharmaceuticals participates in the Swedish Congress Svenska Gastrodagarna in Umeå May 17-20, 2011. Read more
January 21, 2011 Non Regulatory Industrifonden new major shareholder in InDex Pharmaceuticals Read more
May 17, 2010 Non Regulatory Index Pharmaceuticals is present with a booth in the yearly congress Svenska Gatrodagarna in Stockholm 17-20 May, 2010 Read more
December 8, 2009 Non Regulatory Stockholms läns landsting introduces diagnostic test for patients with inflammatory bowel disease Read more
May 18, 2009 Non Regulatory Based on Positive Phase II Results InDex Pharmaceuticals Terminates Kappaproct Study in Advance Read more